Skip to main content

Table 3 BTK inhibitors for relapsed or refractory mantle cell lymphoma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Parameter Ibrutinib Acalabrutinib Zanubrutinib Orelabrutinib LOXO-305
Patients (n) 111 124 86 97 (106) 38
Age (years) 68 68 60.5 NA 69
Prior SCT 11% 18% 3.5% NA 25%
Prior BTKi NA NA NA NA 93%
ORR 67% 80% 84% 87.9% 52%
CR 23% 40% 67.5% 27.4% 25%
DOR (months) 17.5 25.7 19.5 NR NR
Median PFS (months) 13.0 NR 22.1 NR NR
Median OS %, months 47%, 24 87%, 12 84%, 12 88.7%, 12 NR
New A Fib 11% 0% 0% 0%  < 1%
Neutropenia, severe 17% 11% 19.8% NA NA
Pneumonia, severe 6% 6% 9.3% NA NA
Bleeding, severe 6% 2.4% 2.3% 0  < 1%
Reference [40] [39] [38] [37] [41]
  1. A fib, atrial fibrillation; BTKi, Bruton tyrosine kinase inhibitor; NA, not applicable; NR, not reached